Pathology of follicular lymphoma

Katsuyoshi Takata, Tomoko Miyata-Takata, Yasuharu Sato, Tadashi Yoshino

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Follicular lymphoma (FL) is a heterogeneous disease, and there are many different subgroups, such as in terms of age of onset, involved organ (especially extranodal sites such as gastrointestinal tract) and genetic abnormality. Grade 3B is currently regarded as a distinct entity by molecular genetic analyses, but the independence of Grade 3A remains unclear. Variations of clinical course are known in FL. Some cases are very indolent, but others are not. The latter cases show histological transformation to diffuse large B-cell lymphoma (DLBCL) (high-grade transformation) and an aggressive course. Histological transformation to DLBCL is reported to occur in about 30-40% of patients, at a rate of about 3% each year. However, it reaches a plateau at about 16 years, so the stratification of patients in whom transformation would or would not occur is very important for the therapeutic strategy. From genome-wide analysis by next-generation sequencing, EZH2, CREBBP and MLL2, which are histone-modifying genes, have been shown to be frequently mutated in FL and to have an important role in lymphomagenesis. IGH-BCL2 translocation and CREBBP mutations are early events, whereas MLL2 and TNFSFR14 mutations represent late events during disease evolution. In the 2008 WHO classification, three new variants: (1) pediatric follicular lymphoma, (2) primary intestinal follicular lymphoma and (3) in situ follicular lymphoma, are included. Pathologists and clinicians should consider these new developments when deciding on the diagnostic and therapeutic strategy.

Original languageEnglish
Pages (from-to)3-9
Number of pages7
JournalJournal of clinical and experimental hematopathology : JCEH
Volume54
Issue number1
Publication statusPublished - 2014

Fingerprint

Follicular Lymphoma
Pathology
Mutation
Lymphoma, Large B-Cell, Diffuse
Age of Onset
Histones
Non-Hodgkin's Lymphoma
Gastrointestinal Tract
Molecular Biology
B-Lymphocytes
Genome
Pediatrics
Therapeutics
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pathology of follicular lymphoma. / Takata, Katsuyoshi; Miyata-Takata, Tomoko; Sato, Yasuharu; Yoshino, Tadashi.

In: Journal of clinical and experimental hematopathology : JCEH, Vol. 54, No. 1, 2014, p. 3-9.

Research output: Contribution to journalArticle

Takata, Katsuyoshi ; Miyata-Takata, Tomoko ; Sato, Yasuharu ; Yoshino, Tadashi. / Pathology of follicular lymphoma. In: Journal of clinical and experimental hematopathology : JCEH. 2014 ; Vol. 54, No. 1. pp. 3-9.
@article{ce8c8adbf0c64d729c83925af8a79d53,
title = "Pathology of follicular lymphoma",
abstract = "Follicular lymphoma (FL) is a heterogeneous disease, and there are many different subgroups, such as in terms of age of onset, involved organ (especially extranodal sites such as gastrointestinal tract) and genetic abnormality. Grade 3B is currently regarded as a distinct entity by molecular genetic analyses, but the independence of Grade 3A remains unclear. Variations of clinical course are known in FL. Some cases are very indolent, but others are not. The latter cases show histological transformation to diffuse large B-cell lymphoma (DLBCL) (high-grade transformation) and an aggressive course. Histological transformation to DLBCL is reported to occur in about 30-40{\%} of patients, at a rate of about 3{\%} each year. However, it reaches a plateau at about 16 years, so the stratification of patients in whom transformation would or would not occur is very important for the therapeutic strategy. From genome-wide analysis by next-generation sequencing, EZH2, CREBBP and MLL2, which are histone-modifying genes, have been shown to be frequently mutated in FL and to have an important role in lymphomagenesis. IGH-BCL2 translocation and CREBBP mutations are early events, whereas MLL2 and TNFSFR14 mutations represent late events during disease evolution. In the 2008 WHO classification, three new variants: (1) pediatric follicular lymphoma, (2) primary intestinal follicular lymphoma and (3) in situ follicular lymphoma, are included. Pathologists and clinicians should consider these new developments when deciding on the diagnostic and therapeutic strategy.",
author = "Katsuyoshi Takata and Tomoko Miyata-Takata and Yasuharu Sato and Tadashi Yoshino",
year = "2014",
language = "English",
volume = "54",
pages = "3--9",
journal = "Journal of clinical and experimental hematopathology : JCEH",
issn = "1346-4280",
publisher = "Nihon Rinpa Monaikei Gakkai",
number = "1",

}

TY - JOUR

T1 - Pathology of follicular lymphoma

AU - Takata, Katsuyoshi

AU - Miyata-Takata, Tomoko

AU - Sato, Yasuharu

AU - Yoshino, Tadashi

PY - 2014

Y1 - 2014

N2 - Follicular lymphoma (FL) is a heterogeneous disease, and there are many different subgroups, such as in terms of age of onset, involved organ (especially extranodal sites such as gastrointestinal tract) and genetic abnormality. Grade 3B is currently regarded as a distinct entity by molecular genetic analyses, but the independence of Grade 3A remains unclear. Variations of clinical course are known in FL. Some cases are very indolent, but others are not. The latter cases show histological transformation to diffuse large B-cell lymphoma (DLBCL) (high-grade transformation) and an aggressive course. Histological transformation to DLBCL is reported to occur in about 30-40% of patients, at a rate of about 3% each year. However, it reaches a plateau at about 16 years, so the stratification of patients in whom transformation would or would not occur is very important for the therapeutic strategy. From genome-wide analysis by next-generation sequencing, EZH2, CREBBP and MLL2, which are histone-modifying genes, have been shown to be frequently mutated in FL and to have an important role in lymphomagenesis. IGH-BCL2 translocation and CREBBP mutations are early events, whereas MLL2 and TNFSFR14 mutations represent late events during disease evolution. In the 2008 WHO classification, three new variants: (1) pediatric follicular lymphoma, (2) primary intestinal follicular lymphoma and (3) in situ follicular lymphoma, are included. Pathologists and clinicians should consider these new developments when deciding on the diagnostic and therapeutic strategy.

AB - Follicular lymphoma (FL) is a heterogeneous disease, and there are many different subgroups, such as in terms of age of onset, involved organ (especially extranodal sites such as gastrointestinal tract) and genetic abnormality. Grade 3B is currently regarded as a distinct entity by molecular genetic analyses, but the independence of Grade 3A remains unclear. Variations of clinical course are known in FL. Some cases are very indolent, but others are not. The latter cases show histological transformation to diffuse large B-cell lymphoma (DLBCL) (high-grade transformation) and an aggressive course. Histological transformation to DLBCL is reported to occur in about 30-40% of patients, at a rate of about 3% each year. However, it reaches a plateau at about 16 years, so the stratification of patients in whom transformation would or would not occur is very important for the therapeutic strategy. From genome-wide analysis by next-generation sequencing, EZH2, CREBBP and MLL2, which are histone-modifying genes, have been shown to be frequently mutated in FL and to have an important role in lymphomagenesis. IGH-BCL2 translocation and CREBBP mutations are early events, whereas MLL2 and TNFSFR14 mutations represent late events during disease evolution. In the 2008 WHO classification, three new variants: (1) pediatric follicular lymphoma, (2) primary intestinal follicular lymphoma and (3) in situ follicular lymphoma, are included. Pathologists and clinicians should consider these new developments when deciding on the diagnostic and therapeutic strategy.

UR - http://www.scopus.com/inward/record.url?scp=84905817182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905817182&partnerID=8YFLogxK

M3 - Article

VL - 54

SP - 3

EP - 9

JO - Journal of clinical and experimental hematopathology : JCEH

JF - Journal of clinical and experimental hematopathology : JCEH

SN - 1346-4280

IS - 1

ER -